Stay updated on Pembrolizumab in Recurrent HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent HNSCC Clinical Trial page
- Check2 days agoChange DetectedThe page revision tag was updated from v3.3.3 to v3.3.4; no visible changes to study data or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page now displays a new revision note 'Revision: v3.3.3' in the footer, and the 'HHS Vulnerability Disclosure' link along with the prior 'Revision: v3.3.2' note were removed.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page now displays Revision: v3.3.1 and the previous Revision: v3.2.0 label was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved the government funding and operating status notice from the page; core study details are unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedThe screenshots show only cosmetic/UI layout updates with no changes to core study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Recurrent HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.